GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocular Therapeutix Inc (NAS:OCUL) » Definitions » Sloan Ratio %
中文

Ocular Therapeutix (Ocular Therapeutix) Sloan Ratio % : -1.75% (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Ocular Therapeutix Sloan Ratio %?

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

Ocular Therapeutix's Sloan Ratio for the quarter that ended in Dec. 2023 was -1.75%.

As of Dec. 2023, Ocular Therapeutix has a Sloan Ratio of -1.75%, indicating the company is in the safe zone and there is no funny business with accruals.


Ocular Therapeutix Sloan Ratio % Historical Data

The historical data trend for Ocular Therapeutix's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ocular Therapeutix Sloan Ratio % Chart

Ocular Therapeutix Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Sloan Ratio %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -8.33 -38.66 29.38 -5.17 -1.75

Ocular Therapeutix Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Sloan Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.17 -16.35 -9.99 3.36 -1.75

Competitive Comparison of Ocular Therapeutix's Sloan Ratio %

For the Biotechnology subindustry, Ocular Therapeutix's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ocular Therapeutix's Sloan Ratio % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ocular Therapeutix's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where Ocular Therapeutix's Sloan Ratio % falls into.



Ocular Therapeutix Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

Ocular Therapeutix's Sloan Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Sloan Ratio=(Net Income (A: Dec. 2023 )-Cash Flow from Operations (A: Dec. 2023 )
-Cash Flow from Investing (A: Dec. 2023 ))/Total Assets (A: Dec. 2023 )
=(-80.736--70.234
--6.087)/252.06
=-1.75%

Ocular Therapeutix's Sloan Ratio for the quarter that ended in Dec. 2023 is calculated as

Sloan Ratio=(Net Income (TTM)-Cash Flow from Operations (TTM))
-Cash Flow from Investing (TTM))/Total Assets (Q: Dec. 2023 )
=(-80.736--70.234
--6.087)/252.06
=-1.75%

Ocular Therapeutix's Net Income for the trailing twelve months (TTM) ended in Dec. 2023 was -30.318 (Mar. 2023 ) + -20.682 (Jun. 2023 ) + -0.516 (Sep. 2023 ) + -29.22 (Dec. 2023 ) = $-80.74 Mil.
Ocular Therapeutix's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2023 was -19.973 (Mar. 2023 ) + -20.075 (Jun. 2023 ) + -7.732 (Sep. 2023 ) + -22.454 (Dec. 2023 ) = $-70.23 Mil.
Ocular Therapeutix's Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2023 was -3.379 (Mar. 2023 ) + -1.99 (Jun. 2023 ) + -0.259 (Sep. 2023 ) + -0.459 (Dec. 2023 ) = $-6.09 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ocular Therapeutix  (NAS:OCUL) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Dec. 2023, Ocular Therapeutix has a Sloan Ratio of -1.75%, indicating the company is in the safe zone and there is no funny business with accruals.


Ocular Therapeutix Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of Ocular Therapeutix's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


Ocular Therapeutix (Ocular Therapeutix) Business Description

Traded in Other Exchanges
Address
24 Crosby Drive, Bedford, MA, USA, 01730
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Ocular Therapeutix aims to offer medication to replace the existing eye-drop therapy regimen, with the aim of lasting weeks or months with a one-time product application. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
Executives
Summer Road Llc 10 percent owner 207 6TH STREET, WEST PALM BEACH FL 33401
Antony C. Mattessich director C/O OCULAR THERAPEUTIX, INC., 34 CROSBY DR., SUITE 105, BEDFORD MA 01730
Adrienne L Graves director 125 STONE MOUNTAIN CIRCLE, NAPA CA 94558
Rabia Gurses Ozden officer: Chief Medical Officer C/O AKOUOS, INC., 645 SUMMER STREET SUITE 200, BOSTON MA 02210
Philip C. Strassburger officer: General Counsel 24 CROSBY DRIVE, BEDFORD MA 01730
Donald Notman officer: Chief Financial Officer C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD MA 01730
Christopher G White officer: Chief Business Officer C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Jeffrey S. Heier director C/O OCULAR THERAPEUTIX, INC., 34 CROSBY DR., SUITE 105, BEDFORD MA 01730
Merilee Raines director IDEXX LABORATORIES, INC., ONE IDEXX DRIVE, WESTBROOK ME 04092
Lindstrom Richard L Md director 2811 WESTWOOD PL, WAYZATA MN 55391
Opaleye Management Inc. 10 percent owner ONE BOSTON PLACE, SUITE 2600, BOSTON MA 02108
Patricia Kitchen officer: Chief Operations Officer C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD MA 01730
Leslie J. Williams director C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD MA 01730
Seung Suh Hong director C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD MA 01730
Amarpreet Sawhney director, 10 percent owner, officer: President and CEO C/O OCULAR THERAPEUTIX, INC., 36 CROSBY DRIVE, SUITE 101, BEDFORD MA 01730